Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Rated "Buy" by Sell-Side Brokerages

Key Points

• Analysts remain broadly bullish: Twenty-one firms give Definium Therapeutics a consensus “Buy” rating, with an average 12-month price target of $64.88 versus the stock’s $36.17 opening price.
• Recent targets range from $55 to $75, though Wall Street Zen downgraded the shares from “Hold” to “Sell.” The company’s stock has traded between $9.62 and $49.70 over the past year.
• Execution remains a risk: Definium reported quarterly EPS of -$1.44, missing the consensus estimate of -$0.55, while CEO Robert Barrow sold 19,023 shares for approximately $721,733.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) has been assigned a consensus rating of "Buy" from the twenty-one research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $64.88.

A number of analysts have recently weighed in on DFTX shares. Piper Sandler reiterated an "overweight" rating and set a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Needham & Company LLC restated a "buy" rating and set a $66.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the company a "buy" rating in a research report on Friday, August 14th. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. Finally, Wall Street Zen lowered Definium Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th.

Insider Activity

In other news, CEO Robert Barrow sold 19,023 shares of the company's stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total transaction of $721,732.62. Following the completion of the transaction, the chief executive officer owned 1,494,640 shares in the company, valued at approximately $56,706,641.60. This represents a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nykredit A S bought a new position in Definium Therapeutics in the 2nd quarter worth about $45,000. Allworth Financial LP bought a new stake in shares of Definium Therapeutics during the second quarter valued at approximately $110,000. Integrated Wealth Concepts LLC acquired a new position in shares of Definium Therapeutics during the second quarter worth approximately $159,000. NewEdge Advisors LLC acquired a new position in shares of Definium Therapeutics during the second quarter worth approximately $222,000. Finally, WINTON GROUP Ltd bought a new position in Definium Therapeutics in the 2nd quarter worth approximately $240,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX opened at $36.17 on Friday. The company has a market cap of $4.86 billion, a PE ratio of -10.55 and a beta of 2.23. Definium Therapeutics has a fifty-two week low of $9.62 and a fifty-two week high of $49.70. The firm has a 50-day simple moving average of $41.59 and a 200 day simple moving average of $31.69. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, sell-side analysts anticipate that Definium Therapeutics will post -3.02 EPS for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.